Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1749-6632.2002.tb04520.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catestatin as a predictor for cardiac death in heart failure with mildly reduced and preserved ejection fraction.
ESC Heart Fail
February 2025
Department of Cardiology, Peking University First Hospital, Beijing, China.
Article Synopsis
- The study examines how catestatin, a peptide linked to heart disease, predicts cardiac outcomes in patients with different types of heart failure (HF): HF with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF).
- Researchers measured plasma catestatin levels in 228 HF patients and found that its association with cardiac death varied across the different ejection fraction groups during an average follow-up of 52.5 months.
- Elevated plasma catestatin levels were identified as a stronger predictor of cardiac death in patients with HFmrEF/HFpEF than in those with HFrEF, with a significant risk identified at a cut-off level of
Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling.
Mol Cell Biochem
January 2020
Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Fridabad, 121001, India.
Catestatin (CST) is a catecholamine release-inhibitory peptide secreted from the adrenergic neurons and the adrenal glands. It regulates the cardiovascular functions and it is associated with cardiovascular diseases. Though its mechanisms of actions are not known, there are evidences of cross-talk between the adrenergic and CST signaling.
View Article and Find Full Text PDFCatestatin prevents endothelial inflammation and promotes thrombus resolution in acute pulmonary embolism in mice.
Biosci Rep
November 2019
6th Department of Cardiology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, P.R. China.
Catestatin (CTS), a catecholamine-release inhibitory peptide, exerts pleiotropic cardiac protective effects. Pulmonary embolism caused by deep vein thrombosis involving vascular dysfunction. The present study aims to investigate the effects of CTS on thrombus formation that may inhibit the development of pulmonary embolism and its potential pathway.
View Article and Find Full Text PDFCatestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injury-Induced Neointimal Hyperplasia.
Thromb Haemost
January 2018
Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Catestatin, a catecholamine-release inhibitory peptide, has multiple cardiovascular activities. Conflicting results have been recently reported by increased or decreased plasma levels of catestatin in patients with coronary artery disease (CAD). However, there have been no previous reports regarding the effects of catestatin on arteriosclerosis.
View Article and Find Full Text PDFChromogranins: from discovery to current times.
Pflugers Arch
January 2018
Department of Biology, Ecology and Earth Sciences, University of Calabria, Arcavata de Rende, Italy.
The discovery in 1953 of the chromaffin granules as co-storage of catecholamines and ATP was soon followed by identification of a range of uniquely acidic proteins making up the isotonic vesicular storage complex within elements of the diffuse sympathoadrenal system. In the mid-1960s, the enzymatically inactive, major core protein, chromogranin A was shown to be exocytotically discharged from the stimulated adrenal gland in parallel with the co-stored catecholamines and ATP. A prohormone concept was introduced when one of the main storage proteins collectively named granins was identified as the insulin release inhibitory polypeptide pancreastatin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!